CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Choosing points over cash back can be beneficial in specific situations. Understand when to make that switch for better rewards.
27,195 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Travel stocks rarely move in perfect tandem. This guide weighs Booking Holdings and Marriott International to help yo...
Three IRS datapoints can reveal where your tax planning strategies for small business should focus this season. Learn...
UWM raises its offer for Two Harbors to $12.50 per share in cash or 2.3328 UWMC shares, aiming to derail CrossCountry...
As Berkshire's new era unfolds, Greg Abel's first acquisition could set the tone for how the company uses its enormou...
A big bet on a digital banking stock can signal confidence in transformation, but a 30% drop demands careful scrutiny...
Investors are increasingly favoring dividend growth over high yields, signaling a shift toward smaller dividends that...
Facing retirement with half a million in savings can feel intimidating. This guide breaks down how far $500k goes, ho...
A small, overlooked quantum company could ride a wave of lab-to-market commercialization. This guide breaks down why ...
G-III Apparel faces a pivotal year in 2026 as licensing momentum and margin discipline collide with shifting consumer...
Garmin, Synaptics, and QuantumScape blend device hardware, AI-ready tech, and next-gen batteries in a low-profile tri...
As March unfolds, the stock market today, march narrative centers on margins, capex trends, and AI-driven demand. Thi...